Business
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif., June 23, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/e6f2ae2238d2464a2390e86a6028105a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tOTuXAbBzaETavseCtaFlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e6f2ae2238d2464a2390e86a6028105a","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/O3t7ngn9gDItZoSQfbdFGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e6f2ae2238d2464a2390e86a6028105a","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site","length":137,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Evidence of retinal structural improvement persisted out to 3 years","length":67,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Anatomical and functional improvements occur following a single administration of OpRegen cell therapy","length":102,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":306,"olType":false},{"type":"text","content":"CARLSBAD, Calif., June 23, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at Clinical Trials at the Summit (CTS) 2025. The presentation, "OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 36 Results from the Phase 1/2a Trial," was presented by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine, on behalf of Roche and Genentech, a member of the Roche Gro...